Category: Finance
In Case You Missed It: New gold licence for Mantle, Stelar Metals to start lithium drill program
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing [more…]
ASX Large Caps: ASX dips as RBA hands down 25bp hike; Origin shareholders advised to accept offer
ASX ultimately ended in the red beyond today’s RBA decision, down -0.2pc The RBA handed down a 25bp rise at today’s board meeting Origin Energy [more…]
Long Shortz with Arizona Lithium: (D)LEading the pack at Prairie
Arizona Lithium is full steam ahead with DLE test work at its Prairie lithium project in Canada. Stockhead’s Ashtyn Hiron sits down with Arizona Lithium [more…]
ASX Small Cap Lunch Wrap: With no one at the wheel, ASX drifts lower on rates ‘n races day
The local benchmark has fallen in the Tuesday AM, snapping a five-day run of morning victories as investors saved their bets for the horses rather [more…]
Metallurgical test work illuminates the path forward at OD6 Metals’ Splinter Rock project
Metallurgical test results confirm low hydrochloric acid consumption at Splinter Rock, returning an average 6kg HCl/t ore with multiple zones at 6-10kg HCl/t ore Positive [more…]
Resources Top 6: Alderan takes the lead… but here come True North Copper and NickelSearch
Aussie eyes might be on some big horse race or other this arvo, but we’re still focused on the ASX Bursting out the gate, we [more…]
SensOre’s predictive data analytics to pinpoint lithium mineralisation at Firetail Resources’ Yalgoo project
Firetail and JV partner SensOre have identified LCT mineralisation at Yalgoo-Dalgaranga SensOre has completed a farm-in agreement to earn up to 80% of the project [more…]
ASX Health Stocks: Clarity Pharma, Island Pharma set to embark on next steps of clinical trials
Clarity Pharma says 50 patients have been imaged at SABRE trial Island Pharma granted human research ethics approval for ISLA-101 Clarity Pharma imaged 50 [more…]
Race Oncology releases ‘striking’ interim Phase 2 AML trial results
Bisantrene shows promise as treatment in relapsed or refractory acute myeloid leukaemia patients who have run out of options In combination with fludarabine and [more…]
10 at 11ish: Which junior just got a licence to explore next to De Grey’s Hemi gold discovery?
Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live [more…]
